Delivery Order SPE2DB22D3010-SPE2DB26FP0WQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,027.69 to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) on November 5, 2025, with an ultimate completion date of November 28, 2025. This firm fixed-price, non-set-aside contract represents a competitive award for pharmaceutical products supporting federal medical procurement needs. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units) with a contract ceiling value of $3,874.06. The award, issued on October 27, 2025, is structured as a firm fixed price delivery order with an ultimate completion date of November 18, 2025. This non-competitive, non-set-aside award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.9 billion...
- The Defense Logistics Agency awarded a delivery order valued at $3,676.11 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count packages) under a firm fixed-price contract. The delivery order, awarded on October 31, 2025, with an ultimate completion date of November 24, 2025, carries no set-aside designation and represents a competitively awarded transaction. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $4,049.61 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ingrezza 60 mg capsules (30-count packages) valued at $4,049.61. This firm fixed-price delivery order is scheduled for completion by September 2, 2025, with no set-aside designation applied. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $3,676.11 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count) on November 5, 2025, with an ultimate completion date of November 28, 2025. This firm fixed-price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3,676.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 7, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the contractor's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count) valued at $12,083.10 under a firm fixed-price contract type. The award was issued on September 18, 2025, with an ultimate completion date of October 9, 2025, and represents a non-competitive delivery order under the company's existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Ingrezza 60 mg capsules (30-count units) under a firm fixed-price contract with a ceiling value of $4,049.61. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of May 13, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $7,748.14. This firm fixed-price delivery order, which will be completed by November 24, 2025, carries no set-aside designation and represents a competitively awarded transaction. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and falls under the...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB26FP0WQDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count) on November 10, 2025, with a contract ceiling value of $3,676.11 and an ultimate completion date of December 3, 2025. This non-set-aside, competitively awarded delivery order carries firm fixed price terms and will be performed at the vendor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime contract vehicle valued through December 2026 that provides comprehensive global pharmaceutical and medical supply support. As a major pharmaceutical distributor headquartered in Pennsylvania, AmerisourceBergen supplies a diverse portfolio of medications and medical commodities across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems. The company's federal contract portfolio demonstrates consistent capability to fulfill competitive medical procurement requirements across varying transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 11/10/25 |